bluebird bio (NASDAQ: BLUE) reported Q3 EPS of ($0.66), $0.01 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $12.39 million versus the consensus estimate of $13.56 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.